ABSTRACT: Diabetes mellitus independently increases the risk of and mortality from heart failure in a manner that is well established but inadequately understood. Glycemic optimization does not eliminate this risk, and measures of glycemic control are insufficient markers of cardiovascular risk. In response to a regulatory guidance from the US Food and Drug Administration, glucose-lowering agents are now routinely evaluated in large cardiovascular outcome trials. These recent trial experiences of novel and established glucose-lowering therapies have shown variable risks and benefits with respect to heart failure. Cardiovascular outcome trials have increasingly included heart failure events as either a component of the primary end point or a secondary adjudicated end point. We comprehensively review each established and novel currently marketed glucose-lowering therapy, their biological targets, mechanisms of action, and relationships with heart failure. We then highlight gaps in available evidence and directions for future research regarding the ascertainment of heart failure-related data in the evaluation of emerging glucose-lowering therapies.
H
eart failure (HF) and diabetes mellitus (DM) often coexist. In patients with HF, the prevalence of DM is ≈25%, 1-3 a proportion that increases to ≈40% in those hospitalized for HF. [4] [5] [6] Similarly, among individuals with DM, the Framingham Study reported a 2-fold increase in frequency of HF in men and a 5-fold increase in women, independent of coronary artery disease and hypertension. 7 More recent studies further attest to this increased incidence and prevalence of HF patients with DM. [8] [9] [10] Measures of suboptimal glycemic control in DM and impaired insulin sensitivity (even without manifest DM) have been directly correlated with increased risk of developing HF. [11] [12] [13] [14] Both HF and DM closely influence each other, with the onset of one portending a worse prognosis and further disease progression in the other. [15] [16] [17] Given this close relationship, HF is increasingly becoming recognized as an important subset to characterize and end point to study in cardiovascular outcomes trials of glucose-lowering therapies in patients with type 2 DM. In this review, we describe the pathophysiological underpinnings of the DM-HF relationship, mechanistic pathways linking glucose-lowering therapies to HF, and available clinical data regarding the therapeutic effects of these agents in patients with established HF. We then highlight gaps in available evidence and directions for future research regarding the ascertainment of HF-related data in the evaluation of emerging glucoselowering therapies.
Before 2007, the cardiovascular effects of glucose-lowering therapies were not explicitly studied, and the focus was primarily on glycemic control. A meta-analysis of rosiglitazone in 2007, however, revealed that glucose-lowering agents with well-established effects on glycemic indices were still associated with deleterious cardiovascular consequences. This meta-analysis of 42 trials found that rosiglitazone, a thiazolidinedione, was associated with an increased risk of myocardial infarction (MI). 25 Although the end point of death from cardiovascular causes did not reach statistical significance, it caused alarm and led the US Food and Drug Administration (FDA) to propose restrictions on rosiglitazone.
Although larger trials more definitely assessed the cardiovascular safety of rosiglitazone, it became apparent that glucose lowering with available therapies may not translate directly to cardiovascular benefit, as intended, and may in fact result in potential harm in certain cases. As such, in 2008, the FDA issued a regulatory guidance calling for the formal assessment of cardiovascular safety of emerging glucose-lowering agents 26 and provided recommendations on how sponsors should demonstrate that new agents are not linked with an unacceptable increase in cardiovascular risk. These FDA recommendations are outlined in Table 1 . 26 The primary end point designated by this guidance was major adverse cardiovascular events (MACE), a composite of cardiovascular death, nonfatal MI, and nonfatal stroke, as glycemic control was felt to primarily impact the pathways of atherothrombosis. Furthermore, this traditional MACE end point may be less susceptible to ascertainment or misclassification issues compared with other end points (including hospitalization for HF) and thus maximizes potential to detect any signals of risk, if truly present. With growing recognition of the importance of HF in DM, worsening HF as a clinically relevant event is increasingly being considered in contemporary DM trials. Indeed, the incidence and consequences of HF events in DM trials rival if not surpass those of other nonfatal cardiovascular outcomes. 27 For instance, in the EXAMINE trial (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care), hospitalization for HF was associated with the highest relative hazard of postevent mortality compared with other nonfatal cardiovascular events in this high-risk cohort. 28 More recent cardiovascular safety trials of glucose-lowering agents Include patients at higher risk of cardiovascular events: elderly, advanced disease, renal impairment.
Ensure standardized design suitable for metaanalyses and provide protocols to describe statistical methods for such analyses.
Confirm trial duration enough to adequately study long-term cardiovascular risks (eg, minimum 2 y).
Perform meta-analysis with subgroup analysis of important cardiovascular events across phase 2 and 3 controlled clinical trials, if possible.
Completed studies Upper limit of 2-sided 95% CI risk ratio for MACE <1.8 sufficient to demonstrate noninferiority.
If premarketing trial upper limit of 2-sided 95% CI risk ratio of MACE falls between 1.3 and 1.8, subsequent postmarketing trial necessary to show upper limit of 2-sided 95% CI risk ratio of MACE <1.3.
If premarketing trial upper limit of 2-sided 95% CI risk ratio of MACE falls <1.3, subsequent postmarketing trial usually unnecessary.
CI indicates confidence interval; MACE, major adverse cardiovascular event; and MI, myocardial infarction.
Data from the U.S. Food and Drug Administration. 26 have included hospitalization for HF as a part of the primary composite end point, [29] [30] [31] or more commonly as a secondary adjudicated end point, and are providing key insights into this previously underinvestigated topic.
HEART FAILURE OUTCOMES IN TRIALS OF GLUCOSE-LOWERING THERAPIES Insulin
In patients with DM, insulin alters renal handling of sodium and contributes to anti-natriuresis, which when coupled with decreased glycosuria may potentiate fluid retention. 32, 33 Multiple observational studies have suggested that insulin-treated DM was associated with worse outcomes in patients with HF. 34, 35 However, it is difficult to infer a relationship between insulin use and HF risk in an observational setting because insulin-treated patients are generally older, have increased comorbidities, and are at higher risk of cardiovascular complications. 36 In 2012, the ORIGIN trial (Outcome Reduction With an Initial Glargine Intervention) studied the effects of insulin glargine in 12 537 patients with impaired fasting glucose, impaired glucose tolerance, or early type 2 DM at heightened cardiovascular risk (but without prevalent HF, which was an exclusion criterion). Both coprimary end points, traditional MACE or this composite end point plus revascularization or hospitalization for HF, were similar in patients randomized to insulin glargine versus standard therapy. 30 It is noteworthy that inclusion of revascularization and hospitalization for HF nearly doubled observed event rates during the ≈6-year mean follow-up. 30 DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events), another larger cardiovascular outcome trial, compared insulin degludec, an ultralong-acting basal insulin, with another long-acting insulin glargine in patients with or at high risk for cardiovascular disease. 37 Degludec was found to be noninferior and did not adversely impact MACE while lowering rates of severe hypoglycemia. HF hospitalization was not analyzed as a primary or secondary end point in this trial.
Metformin
Metformin is 1 of the most extensively used agents for DM. Its mechanism of action remains somewhat unclear, but it improves insulin sensitivity by decreasing hepatic glucose production and augmenting glucose uptake from skeletal muscles. 38 HF was previously an absolute contraindication to metformin use because of concerns regarding the risk of lactic acidosis, but this was removed as a contraindication in 2007, 39 and metformin is in fact the preferred oral glucose-lowering therapy in patients with HF based on the 2016 European Society of Cardiology guidelines (given its low cost, robust clinician familiarity, and longstanding use as a background therapy). 40 Although there is an absence of large randomized trial evidence supporting the use of metformin in HF patients, observational data have been favorable. Indeed, a meta-analysis of 9 cohort studies of 34 000 patients suggested that metformin was associated with decreased risk of all-cause mortality and hospitalizations compared with other oral glucose-lowering agents (commonly sulfonylureas) without apparent risks of lactic acidosis.
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Acarbose
Acarbose inhibits α-glucosidase, causing delayed breakdown of complex carbohydrates, which impedes glucose absorption. 42 Acarbose is known to increase glucagon-like peptide (GLP) levels. 43 Acarbose remains frequently used in China and Japan, but use is not common in the United States. 36 The STOP-NIDDM trial (STOP-Noninsulin-Dependent Diabetes Mellitus) showed that acarbose delayed transition to incident DM from impaired glucose tolerance compared with placebo but was met with a high premature treatment discontinuation rate (>30%). 44 The ACE trial (Acarbose Cardiovascular Evaluation), a long-term, large-scale trial studying 6522 Chinese patients with established coronary disease and impaired glucose tolerance, included hospitalization for HF as a component of a 5-point composite primary outcome and as a separate prespecified secondary end point. Over median follow-up of 5 years, ACE showed that, although DM occurred less frequently in the acarbose group, there remained no difference in 5-point extended MACE end point between acarbose and placebo. Consistent findings were reported in the subgroup of patients with prior New York Heart Association (NYHA) class I-II HF (advanced HF at baseline was an exclusion criteria). Acarbose did not influence risk of hospitalization for HF compared with placebo (0.43 versus 0.49 admissions per 100 person-years).
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Bromocriptine
Bromocriptine is a D2-dopamine agonist not commonly used but approved for the treatment of type 2 DM. This agent's exact mechanism of action remains unclear; it may suppress hepatic glucose production, 45 lower circulating neurohormonal levels, and contribute to peripheral vasodilation (via vascular dopaminergic effects), which in turn may produce favorable hemodynamic effects in HF. 46 In addition, given its inhibition of prolactin release, there has been growing interest regarding the role of bromocriptine in the treatment of peripartum cardiomyopathy, as a prolactin fragment may contribute to its pathogenesis. 47 The bromocriptine in 3095 patients with type 2 DM. Hospitalization for HF was included as 1 of the adjudicated major cardiovascular events. Bromocriptine reduced the rates of composite cardiovascular events compared with placebo (1.8% versus 3.2% over 52 weeks). However, few HF events were reported, with just 9 patients hospitalized for HF in the bromocriptine group and 6 in the placebo group, 48 and the proportion of patients with baseline HF was not reported.
Sulfonylureas
Sulfonylureas operate by facilitating closure of adenosine-triphosphate-sensitive potassium channels in the plasma membrane of pancreatic β-cells triggering insulin release, which may contribute to treatment-related hypoglycemia and weight gain. 49 The UKPDS 33 (UK Prospective Diabetes Study) evaluated a strategy of intensive glycemic control (with either sulfonylureas or insulin) in 3867 recently diagnosed patients with type 2 DM. Although intensive glycemic control decreased composite DM-related end points compared with a conventional strategy, this was driven by therapeutic effects on microvascular end points, and there was no observed effect with respect to risk of HF. 50 However, more recent observational data have suggested higher mortality and cardiovascular events, including HF, with sulfonylureas, especially in the South Asian and Chinese populations. 51 Another observational cohort study using National Veterans Health Administration databases, a predominantly male population, also showed that when compared with metformin, sulfonylureas are associated with higher risk of both HF-related and cardiovascular death. 52 Potential unintended adverse cardiovascular effects, possibly linked to hypoglycemia, formed the rationale for the ongoing CAROLINA trial (Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes) (NCT 01243424). This large, advanced-phase study with target enrollment >6000 patients with type 2 DM and elevated cardiovascular risk will formally assess the cardiovascular safety of glimepiride, including with respect to risk for hospitalization for HF, a tertiary cardiovascular end point.
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Glinides
Through a mechanism similar to that of sulfonylureas, glinides also stimulate insulin secretion and are associated with weight gain and hypoglycemia. 54 In the NAVIGATOR trial (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research), among 9306 subjects with impaired glucose tolerance who have or are at risk for cardiovascular disease, nateglinide was not found to reduce risk of DM or composite cardiovascular events (which included hospitalization for HF). 31 Risks of hospitalization for HF were similar in nateglinide-and placebo-treated patients (3.1 versus 3.6 events per 100 patient-years). 31 Further data on HF outcomes in patients treated with glinides remain limited.
Thiazolidinediones
Thiazolidinediones serve as ligands for the nuclear peroxisome proliferator-activated receptor γ (PPARγ) that in turn act to decrease hepatic glucose production, increase peripheral glucose uptake, and decrease inflammation. PPARγ activation also increases insulin signaling, making thiazolidinediones powerful insulin sensitizers with minimal risks of hypoglycemia. 55 However, important side effects are observed with this class, including fluid retention and edema, effects that remain mechanistically unclear but seemingly multifactorial. 55 These side effects have limited the use of thiazolidinediones in the HF population since their introduction to the market. PROactive (PROspective Pioglitazone Clinical Trial in Macrovascular Events) compared pioglitazone to placebo in 5238 patients with type 2 DM and established macrovascular disease. Pioglitazone decreased the occurrence of an extended MACE primary end point (that included the traditional MACE composite end point and peripheral artery disease end points) compared with placebo, but this effect did not reach statistical significance. Pioglitazone did significantly reduce the traditional MACE end point, a key secondary outcome, compared with placebo. However, there were numerically higher investigator-reported hospitalizations for HF with pioglitazone (6% versus 4% over average follow-up of ≈3 years). There was no statistically significant difference in HF-related mortality (1% in both arms). PROactive is 1 of the only published studies that reported worsening HF events not requiring hospital admission. 56 Subsequent retrospective review and adjudication of serious HF events in this trial supported this observed safety signal. 57 The RECORD trial (Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes) randomized 4447 subjects (only 0.5% had baseline HF) to rosiglitazone versus a combination of metformin and sulfonylurea. Rosiglitazone reduced average HbA1 c without increasing risk of overall cardiovascular mortality or cardiovascular hospitalization compared with combination metformin and sulfonylurea. However, the trial did reveal an imbalance in risk of hospitalization for HF or HF-related death with rosiglitazone compared with active control (61 patients versus 29 patients; hazard ratio [HR], 2.10; 95% confidence interval [CI], 1.35-3.27). 58 The FDA subsequently requested an independent post hoc review of cardiovascular events in RECORD, which supported the initial findings. Subsequent meta-analyses further confirmed the increased HF risk with thiazolidinedione use. 59, 60 Given these po-tential adverse drug-related effects, these agents are not recommended in patients with symptomatic HF and contraindicated in patients with NYHA class III/IV disease.
60
Glucagon-Like Peptide 1 Receptor Agonists
GLP-1 is an intestinal-derived incretin peptide that stimulates postprandial insulin secretion and inhibits glucagon release. 61 Given that HF can result from impairment in fatty acid and glucose metabolism leading to myocardial insulin resistance, GLP-1 receptor agonists, agents that improve insulin sensitivity, should have theoretical benefit in patients with HF. 62 Several animal and early human studies showed reduction in ischemia and HF with GLP-1 receptor agonists. [63] [64] [65] [66] [67] [68] However, in addition, GLP-1 receptor agonists are known to carry direct myocardial effects, including increased contractility and chronotropy, which may offset these potential benefits. In type 2 DM, several cardiovascular outcome trials have been completed or are underway in the comprehensive evaluation of GLP-1 receptor agonists.
Lixisenatide
In the first published of these cardiovascular safety trials, ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome), 6068 patients with type 2 DM with recent acute coronary syndrome (on average, within 72 days) were randomized to lixisenatide versus placebo and followed for a median of 25 months. 69 HF at baseline was present in 22% of patients. In ELIXA, lixisenatide did not alter the primary composite cardiovascular end point when compared with placebo and did not increase risk of hospitalization for HF (1.8 versus 1.9 events per 100 patient-years), which was included as a secondary adjudicated end point.
Liraglutide
The next safety trial, LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), randomized 9340 patients with type 2 DM at high cardiovascular risk to liraglutide versus placebo and evaluated the primary composite end point of MACE. 70 NYHA class II/III HF represented 1 of the cardiovascular qualifying criteria for trial entry, and ≈18% of patients in either group, at baseline, carried a history of HF. Over median follow-up of 3.8 years, the primary end point occurred in significantly fewer patients receiving liraglutide than placebo (3.4 versus 3.9 events per 100 patient-years), primarily driven by decreased cardiovascular mortality in the liraglutide arm. Fewer patients receiving liraglutide also experienced hospitalization for HF, which was included in a prespecified secondary composite end point, although these results did not reach statistical significance (1.2 versus 1.4 events per 100 patient-years; HR, 0.87; 95% CI, 0.73-1.05; P=0.14). These data formed the basis for the recent expansion of FDA drug labeling in August 2017 to support its use to lower cardiovascular events in adult patients with type 2 DM with established cardiovascular disease.
Liraglutide has been studied in 2 smaller, dedicated phase-2 studies of patients with prevalent HF with reduced ejection fraction (EF) 74 Albiglutide did not show a statistically significant net improvement or worsening in any of the above end points compared with placebo, but it remained well tolerated. Harmony Outcomes (ClinicalTrials.gov. Unique identifier: NCT02465515) is an ongoing phase III trial with an estimated enrollment of 9400 patients seeking to further evaluate the cardiovascular safety of albiglutide.
Dulaglutide
The REWIND trial (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) (ClinicalTrials.gov. Unique identifier: NCT01394952) is currently ongoing to evaluate the cardiovascular safety of dulaglutide in >9600 patients (estimated) with type 2 DM with or at risk for cardiovascular disease.
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Exenatide
Earlier retrospective and crossover studies evaluating exenatide showed cardiovascular benefits and improved hemodynamics in patients with type 2 DM and varying cardiovascular risk factors or HF. 76, 77 The EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering) was a large study that evaluated once-weekly exenatide versus placebo in 14 752 patients with type 2 DM with (≈70%) or without (≈30%) established cardiovascular disease over a median of 3.2 years with a primary composite outcome of first occurrence of MACE. 78 At baseline, 16% of patients had prevalent HF. Of those with baseline HF, 87% were either NYHA class I/II, and 91% had either normal left ventricular EF or mild dysfunction (EF 40% to 55%). The EXSCEL study demonstrated no difference in the primary composite end point (3.7 versus 4.0 events per 100 patient-years) or in the secondary end point of hospitalization for HF (0.9 versus 1.0 events per 100 patient-years) between exenatide and placebo. 79 The primary composite end point was not increased in the subgroup of patients with HF at baseline, despite a higher average heart rate during treatment with exenatide. FREEDOM-CVO (ClinicalTrials.gov. Unique identifier: NCT01455896) is another trial of exenatide (delivered continuously via a miniaturized subcutaneous pump) versus placebo examining its cardiovascular safety in >4000 patients. The study has been completed, and final data have yet to be published, but a preliminary press release from Intarcia Therapeutics, Inc., states that the trial met its primary and secondary clinical end points.
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Dipeptidyl Peptidase-4 Inhibitors
Dipeptidyl peptidase-4 (DPP-4) degrades GLP-1 via proteolysis. DPP-4 inhibitors, in turn, hinder this process and increase the availability of endogenous GLP-1. 61 This stimulates glucose-dependent insulin secretion and inhibits glucagon release.
Alogliptin
In the EXAMINE trial, 5380 patients with type 2 DM and recent acute coronary syndrome were randomized to receive alogliptin or placebo. At baseline, 28% of these patients had a baseline history of HF, although EF was not reported. Over a median follow-up of 18 months, there was no difference in the primary end point of MACE between the 2 groups, 81 and there was a nonsignificant trend to an increase in first hospitalization for HF events with alogliptin compared with placebo (3.1% versus 2.9%; HR, 1.07; 95% CI, 0.79-1.46). Treatment effects on MACE were similar in patients with a baseline history of HF (16.0% in the alogliptin group and 17.2% in the placebo group; treatment-by-HF interaction P=0.87).
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Saxagliptin
In the SAVOR-TIMI 53 study (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53), 16 492 patients with type 2 DM and stable cardiovascular disease or with risk factors for cardiovascular disease (13% with a history of prior HF) were randomized to either saxagliptin or placebo. 83 Over a mean follow-up period of 2.1 years, SAVOR-TIMI 53 revealed no difference between saxagliptin and placebo on the primary MACE end point. However, patients receiving saxagliptin experienced significantly greater rates of hospitalization for HF (a prespecified component of the secondary end point) than those receiving placebo (3.5% versus 2.8%; HR, 1.27; 95% CI, 1.07-1.51; P=0.007), a risk that appeared to be most apparent in the first 12 months of therapy. Event rates were higher in patients with baseline HF (compared with those who did not have HF), but saxagliptin did not significantly increase the risk of MACE in the subgroup with HF (13.9% versus 12.3%; treatment-by-HF interaction P=0.28).
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Sitagliptin
TECOS (Trial Evaluating Cardiovascular Outcomes With
Sitagliptin) assessed the effects of sitagliptin versus placebo in 14 671 patients with type 2 DM and established cardiovascular disease (18% [n=2643] had a diagnosis of prior HF at baseline). 85 TECOS showed that over a median 3-year follow-up, sitagliptin had similar rates of the primary end point of major adverse atherosclerotic events and the secondary end point of hospitalization for HF compared with placebo ( 1.1 versus 1.1 
Vildagliptin
The small, early phase VIVIDD trial (Vildagliptin in Ventricular Dysfunction Diabetes) randomized 254 patients with type 2 DM and NYHA class I-III HF with EF <40% to vildagliptin or placebo. 87, 88 The VIVIDD trial found no significant difference in primary end point of change of EF between the 2 groups, and both groups experienced a decrease in plasma natriuretic peptide levels. There were 23 worsening HF events in the vildagliptin group and 22 in the placebo group. The trial also noted increased left ventricular volumes in the vildagliptin group, a finding that requires further investigation.
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Linagliptin
The risks of HF in the previous trials of DPP-4 inhibitors are discrepant and raise questions regarding the mechanism of this hazard and whether increased risk of HF is class-or drug-specific. Thus far, SAVOR-TIMI 53 is the only trial to show a statistically significant increase in hospitalization for HF. However, based on the potential HF risks with this class, the FDA has recently expanded regulatory warnings and updated product labeling requirements regarding cautious use of saxagliptin, alogliptin, sitagliptin, and linagliptin in patients with HF. Further trials are underway to continue to test the composite safety of this class of therapeutics. One such trial, CAROLINA (NCT 01243424), is currently assessing linagliptin versus glimepiride in patients with type 2 DM and modest cardiovascular risk and includes a secondary end point of hospitalization for HF. 53 A second trial, CARME-LINA (Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus) (NCT 01897532), is evaluating linagliptin in patients with type 2 DM and high cardiovascular risk and either renal dysfunction or high-risk albuminuria. 
Sodium-Glucose Cotransporter-2 Inhibitors
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors prevent glucose reabsorption mainly in the proximal renal tubules by a mechanism independent of insulin. 90 SGLT-2 inhibition also reduces sodium reabsorption by interaction with and inhibition of sodium-hydrogen exchanger (NHE)-3. This subsequently promotes natriuresis, especially given the increased activity of NHE-3 in HF. Furthermore, SGLT-2 inhibitors appear to have multiple other favorable cardiorenal benefits, including attenuation of adverse cardiac remodeling via inhibition of NHE-1 (distributed in the heart and vasculature). 91 Multiple studies on cardiovascular outcomes are currently in progress, and 2 such cardiovascular safety trial programs have been completed.
Empagliflozin
The first published cardiovascular outcome safety trial on SGLT-2 inhibitors was EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes). 92 This trial evaluated 2 doses of empagliflozin in 7020 patients with type 2 DM at high cardiovascular risk (10% with baseline HF) over a median observation time of 3.1 years. EMPA-REG OUTCOME found decreased rates of the overall primary composite end point of traditional MACE between the pooled empagliflozin arms and placebo (10.5% versus 12.1%; HR, 0.86; 95% CI, 0.74-0.99; P=0.04 for superiority).
In addition, the trial demonstrated lower cardiovascular mortality and hospitalization for HF (9.4% versus 14.5%; HR, 0.65; 95% CI, 0.50-0.85) in the empagliflozin groups, a finding that was consistent across all major subgroups, including those with and without baseline HF and regardless of baseline medication use. 93 It is noteworthy that hospitalization for HF was not a component of the primary end point or key secondary end point, and the definition included patients requiring emergency department stays. These data supported its broadened FDA indication in December 2016 for reduction in cardiovascular risk in patients with type 2 DM. Given its potential benefits in the population with HF, empagliflozin is currently being investigated in the treatment of patients with chronic HF 94 
Canagliflozin
Canagliflozin has been studied in a program of 2 paired trials: CANVAS (Canagliflozin Cardiovascular Assessment) and CANVAS-R (CANVAS-Renal). 95 These trials analyzed the effects of canagliflozin in 10 142 participants with type 2 DM at high cardiovascular risk (14% with a history of HF at baseline). Canagliflozin decreased rates of traditional MACE (the primary end point) and hospitalization for HF (a prespecified component of a secondary end point; HR, 0.67; 95% CI, 0.52-0.87). There was no heterogeneity in the effects of canagliflozin in patients with or without baseline cardiovascular disease. 96 The CANVAS program also found decreased progression of renal disease but unexpectedly found an increased risk of amputations with canagliflozin. Further studies are underway to better understand the mechanistic underpinnings of its cardiovascular benefits and to explore this safety signal. The CREDENCE trial (Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy) (ClinicalTrials. gov. Unique identifier: NCT02065791) is 1 such study investigating canagliflozin's effects on cardiovascular and renal outcomes in patients with type 2 DM and established renal impairment.
Dapagliflozin
Dapagliflozin is a particularly selective SGLT-2 inhibitor that has shown decreases in weight, blood pressure, and hemoglobin A1 c in patients with type 2 DM and HF in early-phase investigation. 97 An ongoing cardiovascular outcome trial, DECLARE-TIMI 58 (Dapagliflozin Effect on the Incidence of Cardiovascular EventsThrombolysis in Myocardial Infarction Study Group 58) (ClinicalTrials.gov. Unique identifier: NCT01730534) is a large study (planned enrolled of >17 000 patients) assessing MACE end points and hospitalization for HF in patients with type 2 DM and either established cardiovascular disease or cardiovascular risk factors. The Dapa-HF trial (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) (ClinicalTrials.gov. Unique identifier: NCT03036124) is also currently ongoing and evaluating patients with symptomatic HF (NYHA class II-IV) with reduced EF ≤40%, with an estimated enrollment of 4500 participants.
Ertugliflozin
A cardiovascular outcome trial evaluating ertugliflozin in patients with type 2 DM and vascular disease, VERTIS-CV (ClinicalTrials.gov. Unique identifier: NCT01986881), is currently underway. Secondary end points of VERTIS-CV include hospitalization for HF.
CONCLUSIONS
Patients with type 2 DM are at high risk for developing HF, and its prevention is a major emerging treatment goal. The FDA has now expanded the indications for 2 drugs, empagliflozin and liraglutide, for use for the specific goal of reducing cardiovascular risk. It has become apparent that multiple classes of glucose-lowering therapies have important HF-specific treatment risks and benefits (Table 2 ). For instance, thiazolidinediones are currently not recommended in patients with symptomatic HF and contraindicated in those with NYHA class III/IV HF. DPP-4 inhibitors, particularly saxagliptin and possibly alogliptin, raise concerns for increased risk of hospitalization for HF. Indeed, a study-level meta-analysis of 14 trials including >95 000 patients found differential risks of HF events based on the strategy of glucose lowering with the highest risks associated with peroxisome proliferator-activated receptor agonist and DPP-4 inhibitor classes. 98 However, the SGLT-2 inhibitor class provides promise with respect to improved HF outcomes.
The varied risks of different classes of agents are perhaps explained by underlying mechanisms, in par- ticular their differential effects on insulin (Figure 1 ). Insulin has recognized dose-dependent anti-natriuretic effects through sodium retention in the kidney, which may be sufficient to initiate or worsen HF in susceptible individuals. Agents that enhance this pathway through either provision or sensitization may increase propensity for fluid retention. Insulin secretagogues, such as sulfonylureas and glinides, stimulate pancreatic β-cells to release insulin. We await formal cardiovascular safety assessment of sulfonylureas, especially with respect to HF risk. Incretin-based agents, such as GLP-1 receptor agonists, also contribute to glucose-dependent insulin secretion. Furthermore, these agents increase intracellular cAMP and exert positive Figure 1 . Glucose-lowering therapies, renal sodium handling, and risks of fluid retention. Therapeutic effects on renal sodium handling are highlighted, but other relevant mechanistic pathways contributing to therapy-related heart failure risks and benefits are not described in this figure. DPP-4 indicates dipeptidyl peptidase-4; GLP-1, glucagon-like peptide 1; PPAR, peroxisome proliferator-activated receptor; and SGLT-2, sodium-glucose cotransporter-2. inotropic and chronotropic effects, which could result in increased cardiovascular risk. 99 Similarly, insulin sensitizers, such as thiazolidinediones, are associated with edema and potentially increased HF risk. SGLT-2 inhibitors act independently of insulin to promote natriuresis in the kidneys. SGLT-2 transporters are not expressed in the heart and may carry less direct cardiac-specific effects. They have been shown to lower HF risk and are actively being studied in patients with prevalent HF.
Beyond potential class effects, it is important to note that inferences regarding HF outcomes are dif- ficult to make in trials that were not intended to study such outcomes. Study populations of completed cardiovascular outcome trials largely target patients with established cardiovascular disease or those at high cardiovascular risk (Figure 2 ). More recent trials target patients at higher relative cardiovascular risk with recent acute coronary syndrome. Few trials study patients at low to modest cardiovascular risk, and no published studies have targeted patients with established HF. As such, despite recent progress in defining the cardiovascular risks and benefits of emerging glucose-lowering therapies, there remain important gaps in our understanding of the therapeutic effects of these agents across a spectrum of cardiovascular risk. Ongoing studies that are designed and conducted to target the HF population will provide more clarity as to the benefit and safety of these therapies. Although the routine integration of HF-related imaging and biomarker data in large cardiovascular outcome trials may be costly and logistically challenging, smaller, parallel studies collecting these data may further our mechanistic understanding of these agents with respect to HF risks and benefits. Complementary data emerging from large real-world studies will inform patterns of use and integration of these agents into clinical practice. 100 Hospitalization for HF has only recently been included in the primary composite end point [29] [30] [31] or as a secondary end point in clinical trials of glucoselowering therapies. Continued recognition of the importance of HF outcomes in the population with DM and adjudication of these events in future cardiovascular safety trials is crucial. Future studies (Table 3) should continue to analyze HF outcomes across a spectrum of cardiovascular risks, including dedicated studies targeting the population with HF. We are hopeful this growing body of evidence will clarify the role of glucose-lowering therapies in modifying incident HF risk in patients with type 2 DM and potentially even improve clinical outcomes in patients with prevalent HF.
